US EditionLupin and Zydus sign licensing agreement for co-marketing innovative Semaglutide injection in India
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Lupin and Zydus sign licensing agreement for co-marketing innovative Semaglutide injection in India
Global pharma major Lupin has entered into a Licensing and Supply Agreement with Zydus Lifesciences, an innovation-led life-sciences company, to expand access to innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in India. This partnership brings together Lupin’s extensive reach in the Indian market and Zydus’ robust development capabilities, driven by the shared objective of bringing advanced therapies for…
Zydus, Lupin Partner to Co-Market Semaglutide Injections Ahead of Patent Expiry
Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co-market semaglutide injections in India, positioning themselves ahead of the drug’s upcoming patent expiry. Semaglutide, a GLP-1 receptor agonist, is widely used for treating Type 2 diabetes and has gained popularity for weight management due to its ability to regulate blood sugar levels and appetite. Under the agreement, Lupin will receive semi-exclusive rights…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
